Saeheng Teerachat, Na-Bangchang Kesara, Karbwang Juntra
Department of Clinical Product Development, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Leading Program, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Eur J Clin Pharmacol. 2018 Nov;74(11):1365-1376. doi: 10.1007/s00228-018-2513-6. Epub 2018 Jul 5.
Physiologically based pharmacokinetic (PBPK) modeling, a mathematical modeling approach which uses a pharmacokinetic model to mimick human physiology to predict drug concentration-time profiles, has been used for the discover and development of drugs in various fields, including oncology, since 2000. There have been a few general review articles on the utilization of PBPK in the development of oncology drugs, but these do not include an evaluation of model prediction accuracy. We therefore conducted a systematic review to define the accuracy of PBPK model prediction and its utility throughout all the developmental phases of oncology drugs.
A systematic search was performed in the PubMed, PubMed Central and Cochrane Library databases from 1980 to February 2017 for articles (1) written in English, (2) focused on oncology or antineoplastic or anticancer drugs, tumor or cancer or anticancer drugs listed in the U.S. National Institutes of Health and (3) involving a PBPK model. The absolute-average-folding-errors (AAFEs) of the area under the curve (AUC) between predicted and observed values in each article were calculated to assess model prediction accuracy.
Of the 2341 articles initially identified by our search of the databases, 40 were included in the review analysis. These articles reported on six types of studies, i.e. in vivo (n = 4), first-in-human (n = 5), phase II/III clinical trials (n = 9), organ impairment (n = 3), pediatrics (n = 4) and drug-drug interactions (n = 15). AAFEs of the predicted AUC for all groups of studies were within 1.3-fold of each other despite variations in experimental methodologies.
PBPK modeling is a potential tool which can be effectively applied throughout all phases of oncology drug development. The number of experimental animals and human participants enrolled in the studies can be reduced using PBPK modeling and PBPK-population-PK modeling. The limited number of publications of unsuccessful model application to date may contribute to bias toward the usefulness of modeling.
基于生理学的药代动力学(PBPK)建模是一种数学建模方法,它使用药代动力学模型来模拟人体生理学,以预测药物浓度-时间曲线。自2000年以来,该方法已被用于包括肿瘤学在内的各个领域的药物研发。关于PBPK在肿瘤药物研发中的应用已有几篇综述文章,但这些文章未对模型预测准确性进行评估。因此,我们进行了一项系统综述,以确定PBPK模型预测的准确性及其在肿瘤药物所有研发阶段的效用。
在1980年至2017年2月期间,对PubMed、PubMed Central和Cochrane Library数据库进行系统检索,查找符合以下条件的文章:(1)英文撰写;(2)聚焦于肿瘤学或抗肿瘤或抗癌药物、美国国立卫生研究院列出的肿瘤或癌症或抗癌药物;(3)涉及PBPK模型。计算每篇文章中预测值与观察值之间曲线下面积(AUC)的绝对平均折叠误差(AAFE),以评估模型预测准确性。
在我们检索数据库最初识别出 的2341篇文章中,有40篇纳入综述分析。这些文章报道了六种类型的研究,即体内研究(n = 4)、首次人体研究(n = 5)、II/III期临床试验(n = 9)、器官损害研究(n = 3)、儿科研究(n = 4)和药物-药物相互作用研究(n = 15)。尽管实验方法存在差异,但所有研究组预测AUC的AAFE相互之间在1.3倍以内。
PBPK建模是一种潜在工具,可有效应用于肿瘤药物研发的各个阶段。使用PBPK建模和PBPK群体药代动力学建模可减少研究中纳入的实验动物和人类参与者数量。迄今为止,模型应用不成功的出版物数量有限,这可能导致对建模有用性的偏见。